Michael C. Milone, MD, PhD

Bhoj VG, Kaminski M, Zhao H, Jackson K, Wang W, Liu C, Montgomery RA, Ali N, Mangiola M, Spitzer TR, Safa K, Pattanayak V, Taj R, Chiu J, Bui TM, Sonnenberg EM, Markmann JF, Milone MC, June CH, Siegel DL, Fraietta JA, Gonzalez V, Locci M, Palmer M, Monos D, Hwang WT, Sledge T, Bridges ND, Goldstein JS, Odim J, Sweet SC, Besharatian BD, Hussain SM, Brown NK, Kamoun M, Garfall AL, Naji A. Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy , N Engl J Med, 394: 2026,2117-2125

Frazee CS, Chen S, Berry CT, Lee CS, Banciella RA, Ngo L, Shon D, Herman PJ, Fischman JS, Leff CL, Chen A, Kuo Y, Shestov AA, Kelly AR, Valentic B, Milone MC, O'Connor RS, Ellebrecht CT. Fate induction through asymmetric T cell division is modulated by chimeric antigen receptor costimulatory domains , Nat Immunol: 2026

Gu M, Read KA, Bhardwaj V, Carvalho EJ, Nardo D, Shayne JC, Shukla D, Liu W, Siegel DL, Sheppard NC, Milone MC, Cohen AD, Garfall AL, Riley JL. Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels , J Exp Med, 223: 2026,e20252564

Liu, S., Guruprasad, P., Ramasubramanian, R., Madhu, B., Paruzzo, L., Han, K., Kelly, A., Shestov, A., Xu, H. N., Carturan, A., Zhou, C., Amses, K. R., Afriat, A., Litichevskiy, L., Lin, J., Dubowitz, E., Tangal, N., Zhang, J., McSween, A., Tan, M., Stella, F., Lee, A., Nason, S., Hua, X., Schneider, M., Sleeman, M., Zhang, Y., Gabrielli, G., Yang, Z., Pajarillo, R., Patel, R., Ghilardi, G., Patel, V., Joshi, A., Jiang, S., Jiang, Y., Porazzi, P., Tchou, J. C., Keith, B., Li, M., Chong, E., Schuster, S. J., Milone, M., Rabinowitz, J., O'Connor, R. S., Thaiss, C. A., Levy, M., Ruella, M. β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer , Cell: 2026

Engel NW, Steinfeld I, Ryan D, Anupindi K, Kim S, Wellhausen N, Chen L, Wilkins K, Baker DJ, Rommel PC, Jarocha D, Gohil M, Zhang Q, Milone MC, Fraietta JA, Davis M, Young RM, June CH. Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells , Proc Natl Acad Sci U S A, 122: 2025,e2427216122

Balis FM, Rieger E, Bunin NJ, Gardiner J, Shaw LM, Olson TS, Milone MC. New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis , Cancer Chemother Pharmacol, 95: 2025,32

Zhang, Qian, Wu, Yihao, Yang, Jingyi, Zhou, Kevin, Anand Manoharan, Eric Nigel Ebenezer, Wentz, Tyra, Su, Leon, Yu, Alvin, Wang, Hong-Yi, Bruhn, Laurakay, Steinfeld, Israel, Gonzalez, Nicolas, Song, Edward Z., Zhang, Yunlin, Hresko, Morgan E., Ryan, Daniel E., Engel, Nils W., Nunez-Cruz, Selene, June, Carl H., Garcia, K. Christopher, Milone, Michael C. Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor , Blood Immunology & Cellular Therapy, 1(3): 2025

Zhang Q, Wu Y, Yang J, Zhou K, Manoharan ENEA, Wentz T, Su L, Yu A, Wang HY, Bruhn L, Steinfeld I, Gonzalez N, Song EZ, Zhang Y, Hresko ME, Ryan DE, Engel NW, Nunez-Cruz S, June CH, Garcia KC, Milone MC. Viral vector-free generation of orthogonal IL-2-responsive CAR T cells through gene editing of IL-2 and its receptor , Blood Immunol Cell Ther: 2025

Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I. J., Gabrielli, G., Nasta, S. D., Porazzi, P., Landsburg, D. J., Gerson, J. N., Carter, J., Barta, S. K., Yelton, R., Pajarillo, R., Patel, V., White, G., Ballard, H. J., Weber, E., Napier, E., Chong, E. R., Fraietta, J. A., Garfall, A. L., Porter, D. L., Milone, M. C., O'Connor, R., Schuster, S. J., Ruella, M. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines , Blood Adv, 8(3): 2024,653-666

Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, Liu C, Zhao H, Ochoa T, Parvathaneni K, Xu X, Li E, Gonzalez V, Khadka R, Hoffmann J, Knox JJ, Scholler J, Marcellus B, Allman D, Fraietta JA, Samelson-Jones B, Milone MC, Monos D, Garfall AL, Naji A, Bhoj VG. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies , Cell Rep Med, 4: 2023,101336